Bifidobacterium longum and application thereof

By preparing lyophilized powder of Bifidobacterium longum CGMCC No.20105, the problems of insufficient stability and safety in the existing technology were solved, and the effects of effectively reducing inflammatory response and treating inflammatory diseases were achieved.

CN119040190APending Publication Date: 2024-11-29BRIGHT DAIRY & FOOD CO LTD
View PDF 0 Cites 2 Cited by

Patent Information

Application Number
CN202411183325.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-27
Publication Date
2024-11-29

AI Technical Summary

Technical Problem

Existing technologies struggle to provide a post-biotic product that is highly stable, safe, and reduces inflammation, for the prevention and treatment of inflammatory diseases caused by LPS.

Method used

A strain of Bifidobacterium longum, CGMCC No. 20105, and its lyophilized powder are provided. The lyophilized powder is prepared by boiling water inactivation and lyophilization and can be used in food, health products or medicines to reduce inflammatory response and enhance immune function.

Benefits of technology

Freeze-dried powder can be stored for a long time, has high safety, can effectively reduce inflammatory responses caused by LPS, and can prevent and treat inflammatory diseases caused by LPS pathogens, and has a wide range of product applications.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119040190A_ABST
    Figure CN119040190A_ABST
Patent Text Reader

Abstract

The invention relates to the field of microorganisms, and particularly discloses bifidobacterium longum with the preservation number of CGMCC (China General Microbiological Culture Collection Center) No.20105. The strain with the preservation number of CGMCC No.20105 is a long bifidobacterium longum subspecies and is an edible fungus strain, and the food safety can be guaranteed. The inactivated CGMCC No.20105 can be stored for a long time after being freeze-dried, has the effect of reducing proinflammatory factors of macrophages caused by LPS and NO production after being taken, and has very good applicability to prevention and treatment of inflammatory diseases caused by LPS and pathogenic bacteria containing LPS pathogenicity. The inactivated freeze-dried CGMCC No.20105 has the characteristics of inactivity and stability, can be widely applied to foods, dietary supplements, fermented products and the like, and has very good product processability.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of microorganisms, and in particular to a Bifidobacterium longum and its application. Background Art

[0002] Lipopolysaccharide is one of the components of the outer membrane of most Gram-negative bacteria. In order to avoid being hunted by the host immune system, pathogenic bacteria usually adopt two escape strategies. One is to disguise the immune stimulatory components on the surface of the bacteria, making it difficult for the host to monitor; the second is to inhibit the activation of the immune system to avoid fatal immune responses. LPS acts as a protective barrier for bacteria, and its three main components are all involved in the process of bacteria escaping the immune system. First, the lipid A part of the bacteria will undergo two modifications to help the bacteria escape immune recognition: ① By removing phosphates or adding modifying groups to change the total charge on the surface of the bacteria, resistance to the innate immune system is enhanced; ② The lipid A structure undergoes acylation modification to help bacteria avoid monitoring by the host immune system. In addition, antigenic variation in bacteria can also help bacteria escape immune recognition. After the bacteria that have escaped the catastrophe release LPS in the host, the host's internal environment will be in a disordered state, causing inflammatory diseases. As a non-specific immunogen, LPS interacts with host effector cells (mainly monocytes, macrophages and neutrophils) to secrete bioactive molecules such as tumor necrosis factor-α (TNF-α), interleukin 1 (IL-1), interleukin 2 (IL-2), interleukin 6 (IL-6), reactive oxygen free radicals (ROS), carbon monoxide (NO), etc. after entering the microcirculation, causing clinical syndromes such as fever, disseminated intravascular coagulation, multiple organ failure and shock. The toxicity of LPS is that LPS forms a protective barrier around bacteria to escape the effects of antibiotics, acts on host cells, produces inflammatory cytokines, and makes the internal environment of the body in a disordered state, causing diseases such as endotoxemia and sepsis.

[0003] Probiotics are widely used in the treatment of various diseases. Bifidobacterium is a strictly anaerobic, Gram-positive, polymorphic rod-shaped bacterium of the Actinomycetes phylum. The end is often bifurcated, hence the name bifidobacterium. It is an important core flora and beneficial physiological flora in the intestines of humans and animals. Due to the rise of microecology and the progress of the medical revolution in the past two decades, the importance of bifidobacterium research has been increasingly recognized. As bifidobacterium products are widely used around the world, the general public has recognized its importance. In particular, it can provide unique protection for the intestinal health of infants and young children, and effectively reduce the incidence of intestinal infections in infants and young children. The main role and wide application of bifidobacteria have also laid the foundation for the development of bifidobacterium research. After continuous exploration and experiments by many experts and scholars, it has been confirmed that bifidobacteria are the most beneficial flora in the intestine, and the reduction or disappearance of the number of bifidobacteria is a sign of "unhealthy" status.

[0004] The International Scientific Association of Probiotics and Prebiotics (ISAPP) defines postbiotics as "preparations of inanimate microorganisms and / or their components that are beneficial to the health of the host". Postbiotics are inactivated by a specific method to make the originally active microorganisms lose their activity and growth and reproduction ability, but at the same time retain the microbial structure, characteristics and efficacy to a certain extent. Postbiotics have very good industrial and product applicability. ① Stability: Maintaining the activity of microorganisms is a challenge because many probiotics are sensitive to oxygen and heat, but for inanimate microorganisms, it is easy to obtain products with a long shelf life. Compared with probiotics, postbiotics are more suitable for geographical areas where there is no reliable cold chain or environmental temperature that causes problems in the storage of live microorganisms. ② Intellectual property rights: It is impossible to separate microorganisms derived from postbiotics from commercial products, allowing product developers to maintain ownership of their ingredients. ③ Safety: Since the microorganisms contained in postbiotics have lost their ability to replicate, they will not cause bacteremia. Due to the good characteristics of postbiotics, the industry has regarded postbiotics as the fourth generation of microecological products after probiotics, prebiotics and synbiotic preparations. At the same time, driven by the improvement of people's health awareness and the increase in demand for healthy food, postbiotics are gradually gaining popularity due to their diverse potential effects and good stability.

[0005] Therefore, screening postbiotics with independent intellectual property rights that have the ability to reduce inflammatory responses, are stable and have strong applicability has very good value and prospects. Summary of the invention

[0006] In order to prepare a postbiotic that has the function of reducing inflammatory response, is stable and has strong applicability, the present application provides a Bifidobacterium longum, whose preservation number is CGMCC No.20105.

[0007] The deposit information of the strain in this application is as follows:

[0008] Strain name: Bifidobacterium longum subsp. longum

[0009] The accession number is: CGMCC No.20105;

[0010] Deposit date: June 18, 2020;

[0011] Name of depository: General Microbiology Center of China Microbiological Culture Collection Administration;

[0012] Abbreviation of depository unit: CGMCC;

[0013] Address of the preservation unit: No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing.

[0014] The present application also provides a freeze-dried powder, which is prepared from the above-mentioned Bifidobacterium longum.

[0015] The present application also provides a method for preparing the above-mentioned lyophilized powder, which comprises lyophilizing the above-mentioned Bifidobacterium longum to obtain the lyophilized powder.

[0016] The present application also provides the use of the above-mentioned Bifidobacterium longum or the above-mentioned lyophilized powder in the preparation of foods, health products or medicines for preventing and / or treating inflammatory diseases; and / or, in the preparation of foods, health products or medicines for reducing TNF-α, IL-6 or NO secretion; and / or, in the preparation of foods, health products or medicines for enhancing immune function.

[0017] The present application also provides a food, a health product or a medicine, wherein the food, the health product or the medicine contains the above-mentioned Bifidobacterium longum or the above-mentioned lyophilized powder.

[0018] The beneficial effects brought by the present application include but are not limited to: (1) CGMCC No. 20105 is a subspecies of Bifidobacterium longifolium, which is an edible strain and food safety can be guaranteed. (2) The inactivation method is a 2-minute boiling water bath, which is easy to operate and has strong applicability. (3) The inactivated CGMCC No. 20105 can be stored for a long time after freeze-drying. Ingestion has the effect of reducing the pro-inflammatory factors and NO production of macrophages caused by LPS, and has very good applicability for the prevention and treatment of inflammatory diseases caused by LPS and pathogenic bacteria containing LPS. (4) Due to its inactive and stable characteristics, it can be widely used in food, dietary supplements, fermented products, etc., and has very good product processability. BRIEF DESCRIPTION OF THE DRAWINGS

[0019] The present application will be further described in the form of exemplary embodiments, which will be described in detail with reference to the accompanying drawings. These embodiments are not restrictive, and include:

[0020] Figure 1 Figure 2 is a diagram of colony morphology according to some embodiments of the present application.

[0021] Figure 2 The figure is a diagram of the results of Gram staining microscopy of colonies according to some embodiments of the present application.

[0022] Figure 3 The following are the results of scanning electron microscopy of the colonies according to some embodiments of the present application.

[0023] Figure 4 The following are the results of gene sequence comparison of the colonies shown in some embodiments of the present application.

[0024] Figure 5 This is a graph showing the detection results of the pro-inflammatory cytokine TNF-α according to some embodiments of the present application.

[0025] Figure 6 This is a graph showing the detection results of the pro-inflammatory cytokine IL-6 according to some embodiments of the present application.

[0026] Figure 7 This is a graph showing the detection results of NO content according to some embodiments of the present application.

[0027] Figure 8 It is an experimental flow chart according to some embodiments of the present application.

[0028] Fig. 9 This is a graph showing the detection results of the pro-inflammatory cytokine TNF-α according to some embodiments of the present application.

[0029] Fig.10 This is a graph showing the detection results of the pro-inflammatory cytokine IL-6 according to some embodiments of the present application.

[0030] Fig.11 This is a graph showing the detection results of the pro-inflammatory cytokine TNF-α according to some embodiments of the present application.

[0031] Fig.12 This is a graph showing the detection results of the pro-inflammatory cytokine IL-6 according to some embodiments of the present application. DETAILED DESCRIPTION

[0032] In order to more clearly illustrate the technical solutions of the embodiments of this specification, the following is a brief introduction to the drawings required for the description of the embodiments. Obviously, the drawings described below are only some examples or embodiments of this specification. For ordinary technicians in this field, this specification can also be applied to other similar scenarios based on these drawings without creative work. Unless it is obvious from the language environment or otherwise explained, the same reference numerals in the figures represent the same structure or operation.

[0033] As shown in this specification and claims, unless the context clearly indicates an exception, the words "a", "an", "an" and / or "the" do not refer to the singular and may also include the plural. Generally speaking, the terms "comprise" and "include" only indicate the inclusion of the steps and elements that have been clearly identified, and these steps and elements do not constitute an exclusive list. The method or device may also include other steps or elements.

[0034] Flowcharts are used in this specification to illustrate the operations performed by the system according to the embodiments of this specification. It should be understood that the preceding or following operations are not necessarily performed precisely in order. Instead, the steps may be processed in reverse order or simultaneously. At the same time, other operations may also be added to these processes, or one or more operations may be removed from these processes.

[0035] The present application provides a Bifidobacterium longum, whose preservation number is CGMCC No.20105.

[0036] In some embodiments, the 16S rRNA coding sequence of Bifidobacterium longum may include the nucleotide sequence shown as SEQ ID NO.1.

[0037] The present application also provides a freeze-dried powder, which is prepared from the above-mentioned Bifidobacterium longum.

[0038] Lyophilized powder is a powdered product made through freeze-drying technology, which involves freezing the liquid containing the active ingredient at extremely low temperatures and then removing the water through vacuum drying, leaving a dry powder. Lyophilized powder can maintain the stability and biological activity of the active ingredient and is commonly used in the pharmaceutical, biological products, cosmetics and food industries.

[0039] In the pharmaceutical field, freeze-dried powder is often used to preserve bioactive substances such as vaccines, blood products, and antibiotics. In cosmetics, freeze-dried powder may contain active ingredients with repairing, anti-aging, or whitening effects. In the food industry, freeze-drying technology is used to produce freeze-dried fruits and vegetables to preserve the nutrients and flavor of food.

[0040] When using freeze-dried powder, it is usually necessary to mix it with a specific solvent (such as water) to restore its original liquid form and activity. Since freeze-dried powder does not require refrigeration during storage and transportation, it has a long shelf life and good stability.

[0041] In some embodiments, the Bifidobacterium longum may be inactivated Bifidobacterium longum.

[0042] In this application, inactivation refers to the process of making an organism or its components (such as viruses, bacteria, cells, etc.) lose their activity or pathogenicity.

[0043] The present application also provides a method for preparing the above-mentioned lyophilized powder, which comprises lyophilizing the above-mentioned Bifidobacterium longum to obtain the lyophilized powder.

[0044] In some embodiments, the Bifidobacterium longum can be washed, inactivated, and freeze-dried to obtain a freeze-dried powder.

[0045] In some embodiments, the Bifidobacterium longum can be washed using double distilled water.

[0046] In some embodiments, the inactivation condition can be boiling water inactivation.

[0047] In some embodiments, the inactivation time may be 1 to 5 minutes. In some embodiments, preferably, the inactivation time may be 2 minutes.

[0048] In some embodiments, the lyophilization condition can be -80°C vacuum freezing.

[0049] In some embodiments, the lyophilization time may be ≥ 2 hours.

[0050] The present application also provides the use of the above-mentioned Bifidobacterium longum or the above-mentioned lyophilized powder in the preparation of foods, health products or medicines for preventing and / or treating inflammatory diseases; and / or, in the preparation of foods, health products or medicines for reducing TNF-α, IL-6 or NO secretion; and / or, in the preparation of foods, health products or medicines for enhancing immune function.

[0051] The term "prevention and / or treatment" (and grammatical variations thereof) refers to an attempt to alter the natural course of a disease in a treated individual, and may be a clinical intervention performed for prevention or during the course of clinical pathology. Desired effects of treatment include, but are not limited to, preventing the occurrence or recurrence of the disease, alleviating symptoms, reducing any direct or indirect pathological consequences of the disease, preventing metastasis, slowing the rate of disease progression, ameliorating or alleviating the disease state, and eliminating or improving prognosis.

[0052] In some embodiments, the inflammatory disease may be caused by LPS or pathogenic bacteria containing LPS. In some embodiments, preferably, the inflammatory disease may be caused by LPS causing macrophages to secrete proinflammatory factors TNF-α, IL-6 or NO.

[0053] Inflammatory diseases are a class of diseases that are caused by inflammation of body tissues due to various factors. Inflammatory diseases can be divided into many types, including autoinflammatory diseases, idiopathic inflammatory myopathy, inflammatory bowel disease, etc., and each type of inflammatory disease has its own specific pathological mechanism and clinical manifestations.

[0054] Inflammation is a basic pathological process and can be a defensive response caused by stimuli such as trauma and infection. The local manifestations of inflammation are redness, swelling, heat, pain and dysfunction, and may also be accompanied by systemic reactions such as fever and changes in white blood cell counts. Inflammation can be a beneficial defensive response, but sometimes it is also harmful, such as attacking one's own tissues or inflammation occurring in transparent tissues.

[0055] The present application also provides a food, a health product or a medicine, wherein the food, the health product or the medicine contains the above-mentioned Bifidobacterium longum or the above-mentioned lyophilized powder.

[0056] In the present application, the food, health product or medicine can be in solid form, such as capsules, tablets, pills, granules, sachets or lozenges; or can be in liquid form, such as solutions, suspensions, emulsions or syrups; or can be in powder form, such as freeze-dried powder.

[0057] The drug also includes a pharmaceutically acceptable carrier. The pharmaceutically acceptable carrier may be a commonly used drug carrier, such as poly(ethylene glycol), including poly(ethylene glycol) with a molecular weight ranging from about 200 to about 5,000 Da (e.g., PEG 200, PEG 300, PEG 400, or PEG 600), ethylene glycol, propylene glycol, glycerol, nonionic surfactants, tyloxapol, polysorbate 80, polyethylene glycol-15-hydroxy, stearate, phospholipids, lecithin, dimyristoylphosphatidylcholine, dipalmitoylphosphatidylcholine, distearoylphosphatidylcholine, cyclodextrin, α-cyclodextrin, β-cyclodextrin, γ-cyclodextrin, hydroxyethyl-β-cyclodextrin, hydroxypropyl-β-cyclodextrin, hydroxyethyl-γ-cyclodextrin, hydroxypropyl-γ-cyclodextrin, dihydroxypropyl-β-cyclodextrin, sulfobutyl ether-β-cyclodextrin, sulfobutyl ether-γ-cyclodextrin The invention relates to a pharmaceutical composition comprising the following: a pharmaceutical composition comprising: a hydroxypropyl methylcellulose, a hydroxypropyl cellulose, a polyvinyl pyrrolidone, a vinyl acetate copolymer, a vinyl pyrrolidone, a sodium lauryl sulfate, a sodium dioctyl sulfosuccinate, or any combination thereof. A person skilled in the art can generally determine the formulation of a drug based on the dosage form requirements.

[0058] In some embodiments, the drug of the present application can be administered in a monotherapy (e.g., without any additional therapeutic agent being administered concomitantly, or without any additional therapeutic agent being administered concomitantly against the same disease to be treated or prevented by the drug of the present application). In some embodiments, the drug of the present application can also be administered in combination with one or more other therapeutic agents or administered simultaneously.

[0059] The experimental methods in the following examples are conventional methods unless otherwise specified. The experimental materials used in the following examples are purchased from conventional biochemical reagent companies unless otherwise specified. The quantitative tests in the following examples are repeated three times, and the results are averaged.

[0060] Example 1

[0061] (1) Strain screening and identification

[0062] The feces of a child, a male from Shanghai (92 years old, healthy), and a female from Jiangsu (24 years old, healthy) were dissolved in sterile water and diluted tenfold, spread on TPY medium, and cultured anaerobically at 37 degrees for 16 hours to obtain three purified bacterial strains, which were named BD3150 (see Figure 1), BD6256 and BD8263, pick a single colony for Gram staining microscopy (such as Figure 2 Scanning electron microscopy was used for further morphological observation (as shown in Figure 3 shown).

[0063] (2) Extraction of bacterial genomic DNA

[0064] ① Collect 1.0×10 9 Centrifuge the bacterial culture (OD600 of 1 ml bacterial solution is 1-1.5) at 12,000×g for 30 seconds, discard the supernatant, and resuspend the precipitate with 150 μl of Buffer S to which RNase A has been added.

[0065] ② Add 20 μl of lysozyme storage solution, mix well, and let stand at room temperature for 5 minutes.

[0066] ③ Add 30 μl 0.25 M EDTA (pH 8.0), mix well, and place on ice for 5 min.

[0067] ④Add 450 μl Buffer GA, vortex for 15 seconds, and incubate in a 65°C water bath for 10 minutes.

[0068] ⑤ Add 400 μl Buffer GB and 1 ml Buffer DV (precooled at 4°C), mix vigorously, and centrifuge at 12,000×g for 2 min.

[0069] ⑥ Discard the upper phase as much as possible, retain the interphase precipitate and the lower phase. Add 1 ml of 4℃ pre-cooled Buffer DV, mix vigorously, and centrifuge at 12,000×g for 2 minutes.

[0070] ⑦ Discard the upper phase and transfer the lower phase to a filter (the filter is placed in a 2 ml centrifuge tube). Centrifuge at 12,000×g for 1 min.

[0071] ⑧Discard the filter, add 400μl Buffer BV to the filtrate and mix well.

[0072] ⑨ Place the preparation tube in a 2 ml centrifuge tube, transfer the mixed solution in step 8 into the preparation tube, and centrifuge at 12,000×g for 1 min.

[0073] ⑩Discard the filtrate, place the preparation tube back into the original 2 ml centrifuge tube, add 500 μl Buffer W1, and centrifuge at 12,000×g for 1 min.

[0074] Discard the filtrate, place the preparation tube back into the original 2 ml centrifuge tube, add 700 μl Buffer W2, and centrifuge at 12,000 × g for 1 min.

[0075] Wash once more with 700 μl Buffer W2 in the same manner.

[0076] The filtrate was discarded, and the preparation tube was placed back into the original 2 ml centrifuge tube and centrifuged at 12,000 × g for 1 min.

[0077] Place the preparation tube in another clean 1.5 ml centrifuge tube, add 100-200 μl of Eluent or deionized water to the center of the silica membrane, let stand at room temperature for 1 minute, and centrifuge at 12,000 × g for 1 minute to elute the DNA.

[0078] (3) Bacterial genome PCR amplification primers are shown in Table 1:

[0079] Table 1 Primer design

[0080]

[0081] For the PCR amplification reaction system, add the following components from Table 2 into a 0.2 ml centrifuge tube:

[0082] Table 2 PCR amplification reaction system

[0083]

[0084] Mix by flicking gently, collect the droplets on the tube wall to the bottom of the tube by instant centrifugation, and perform PCR reaction on a PCR amplification instrument. The reaction parameters are shown in Table 3 below:

[0085] Table 3 PCR amplification reaction program

[0086]

[0087] After the reaction was completed, 3 μL of PCR product was taken for 1% agarose gel electrophoresis to confirm the PCR amplified fragment.

[0088] (4) Recovery of PCR products

[0089] The PCR product was recovered using the AxyPrep DNA gel recovery kit. The specific operation was carried out according to the kit instructions. The steps are as follows:

[0090] ① Under ultraviolet light, cut the agarose gel containing the target DNA, put it into a clean centrifuge tube, and weigh it.

[0091] ② Add 3 gel volumes of Buffer DE-A, mix well and heat at 75℃ until the gel blocks are completely melted.

[0092] ③ Add 0.5 volume of Buffer DE-B to Buffer DE-A and mix well; when the separated DNA fragment is less than 400 bp, add 1 gel volume of isopropanol.

[0093] ④ Transfer the mixture to a DNA preparation tube and centrifuge at 12,000×g for 1 min. Discard the filtrate.

[0094] ⑤ Place the preparation tube back into a 2 ml centrifuge tube, add 500 μl Buffer W1, centrifuge at 12,000 × g for 30 seconds, and discard the filtrate.

[0095] ⑥Put the preparation tube back into a 2 ml centrifuge tube, add 700 μl Buffer W2, centrifuge at 12,000 × g for 30 seconds, and discard the filtrate. Use the same method to add 700 μl Buffer W2 and centrifuge at 12,000 × g for 1 minute.

[0096] ⑦ Place the preparation tube back into a 2 ml centrifuge tube and centrifuge at 12,000×g for 1 min.

[0097] ⑧Place the preparation tube in a clean 1.5ml centrifuge tube (provided in the kit), add 25-30μl of deionized water to the center of the preparation membrane, let stand at room temperature for 1min. Centrifuge at 12,000×g for 1min to elute the DNA.

[0098] (5) Sequence determination and analysis

[0099] The purified PCR products of each bacterial strain were sequenced using a sequencer ABI3730-XL. The sequencing results showed that the sequences of the three colonies were the same.

[0100] (6) Sequence analysis

[0101] The spliced ​​sequence files were compared with the data in the NCBI 16S database using the NCBI Blast program to obtain the species information with the greatest sequence similarity to the species to be tested (e.g. Figure 4 The results of the identification were shown in Figure 2. After comparison and identification, it was found to be Bifidobacterium longum subspecies longum, and its physical and chemical properties were consistent with the characteristics of Bifidobacterium longum subspecies longum.

[0102] >BD3150, BD6256 and BD8263 16S rRNA coding sequences

[0103]

[0104] Example 2 - Cultivation of Bifidobacterium longum

[0105] Take a -80℃ frozen Bifidobacterium longum freeze-dried tube (laboratory preserved bacteria), activate it on a TPY plate, and after anaerobic culture at 37℃ for 48h, select a single bacterium and inoculate it into MRS liquid medium containing 0.5‰ cysteine ​​and culture it at 37℃ for 24h. 5% inoculation activation, inoculate the activated Bifidobacterium longum subspecies BD3150, BD8263, and BD6256 into the seed liquid and fermentation medium. The formula of solid culture medium and liquid fermentation medium is as follows:

[0106] Plate solid medium (TPY):

[0107] 10g hydrolyzed casein, 5g plant peptone, 2g yeast extract powder, 5g glucose, 0.5g L-cysteine, 2g dipotassium hydrogen phosphate, 0.5g magnesium chloride, 0.25g zinc sulfate, 0.15g calcium chloride, 0.0001g ferric chloride, 1g Tween 80, add distilled water to make up to 1L, pH=6.5, add 12g agar, sterilize at 121℃ high pressure for 20min, cool to about 50℃, pour into plates and store for later use.

[0108] MRS liquid medium:

[0109] Peptone 10g, beef extract powder 8g, yeast extract powder 4g, glucose 20g, dipotassium hydrogen phosphate 2g, diammonium hydrogen citrate 2g, sodium acetate 5g, magnesium sulfate 0.2g, manganese sulfate 0.04g, Tween 80 1g, add distilled water to make up to 1L, pH = 5.7, autoclave at 121℃ for 20min, cool and store for later use.

[0110] Seed culture medium and fermentation liquid

[0111] Peptone 10g, beef extract powder 8g, yeast extract powder 4g, glucose 20g, dipotassium hydrogen phosphate 2g, diammonium hydrogen citrate 2g, sodium acetate 5g, magnesium sulfate 0.2g, manganese sulfate 0.04g, Tween 80 1g, L-cysteine ​​0.5g, add distilled water to make up to 1L, pH = 5.7, autoclave at 121℃ for 20min, cool and store for later use.

[0112] Example 3 - Inactivation and freeze-drying of Bifidobacterium longum strains

[0113] The strains of Bifidobacterium longum subsp. longum were collected by centrifugation at 7000 rpm and washed with double distilled water. The cells were resuspended in double distilled water and inactivated in a boiling water bath for 2 min. After cooling to room temperature, the cells were centrifuged and the supernatant was discarded, and the cells were retained. They were freeze-dried at -80°C for more than 2 hours and freeze-dried overnight in a vacuum freezer.

[0114] Example 4 - Cell experiment

[0115] Weigh the inactivated freeze-dried long bifidobacterium and add it to DMEM cell culture medium containing 10% FBS and 1% penicillin-streptomycin at a concentration of 100-200 μg / mL.

[0116] (1) Determination of the effect of inactivated Bifidobacterium longum on the production of pro-inflammatory cytokines TNF-α and IL-6 by RAW264.7 cells before LPS

[0117] On the first day, 5×10 5 / well were inoculated in a 12-well cell culture plate. The next day, DMEM complete medium containing inactivated long bifidobacterium was added to the cells and incubated for 12 hours. DMEM complete medium was added to the control. Both were replaced with DMEM complete medium containing 1μg / mL LPS (Ecoli 0111: B4), 5% CO2, 37℃ for 12 hours. The cell culture supernatant was aspirated, centrifuged at 8000rpm for 5min, and the supernatant was collected, aliquoted and frozen at -80℃ for ELISA determination of inflammatory cytokines TNF-α and IL-6. The results are shown in Figure 5 and Figure 6 shown.

[0118] (2) Determination of NO

[0119] On the first day, 1×10 4 / well was inoculated in a 96-well plate, and cultured at 37℃ with 5% CO2 for 24h. The culture medium was discarded, and the cells were washed with PBS. DMEM complete medium containing inactivated long bifidobacterium was added to the cells and incubated for 12h. DMEM complete medium was added to the control. DMEM complete medium containing 1μg / mL LPS (Ecoli 0111: B4) was replaced, and cultured at 37℃ with 5% CO2 for 12h. The cell culture supernatant was aspirated, centrifuged at 8000rpm for 5min, and the supernatant was collected. The NO content was determined using the NO kit. The standard curve was prepared by gradient dilution of NaNO2. 50μL of sample and standard curve were added to the 96-well plate respectively, and 50μL of Griess Reagent I was added accordingly. Then 50μL of Griess Reagent II was added to each well. The absorbance value at 540nm was measured within 10min, and the NO content in the cell culture supernatant was calculated by the standard curve. The results are shown in Figure 7 shown.

[0120] The results of TNF-α, IL-6 and NO content determination show that inactivated Bifidobacterium longifolium BD3150, as a postbiotic, has a very good effect in reducing the production of inflammatory immune factors TNF-α, IL-6 and NO caused by LPS, and has a very good effect in preventing inflammatory damage caused by LPS.

[0121] (3) Determination of pro-inflammatory cytokines TNF-α and IL-6 produced by RAW264.7 cells after intervention with LPS and BD3150

[0122] On the first day, 5×10 5 / well were inoculated in a 12-well cell culture plate. The next day, DMEM complete medium containing inactivated long bifidobacterium 200 μg / mL BD3150 and 1 μg / mL LPS (Ecoli 0111: B4) was added to the cells and cultured at 5% CO2 and 37°C for 12 h and 24 h. The cell culture supernatant was aspirated and centrifuged at 8000 rpm for 5 min. The supernatant was collected, aliquoted and frozen at -80°C for the ELISA method to determine the content of pro-inflammatory cytokines TNF-α and IL-6. The results are shown in Fig. 9 and Fig.10 shown.

[0123] (4) Determination of pro-inflammatory cytokines TNF-α and IL-6 produced by RAW264.7 induced by adding BD3150 after LPS intervention

[0124] On the first day, 5×10 5 / well were inoculated in a 12-well cell culture plate. The next day, DMEM complete medium containing 1 μg / mL LPS (Ecoli 0111: B4) was added to the cells and incubated for 12 hours. Then, inactivated long bifidobacterium 200 μg / mL BD3150 was added to the culture medium and cultured for 12 hours at 5% CO2 and 37°C. The cell culture supernatant was aspirated, centrifuged at 8000 rpm for 5 minutes, and the supernatant was collected, aliquoted and frozen at -80°C for determination of the content of pro-inflammatory cytokines TNF-α and IL-6 by ELISA. The results are shown in Fig.11 and Fig.12 shown.

[0125] The results of TNF-α and IL-6 content determination show that inactivated Bifidobacterium longifolium BD3150, as a postbiotic, has a very good effect in reducing the production of proinflammatory cytokines TNF-α and IL-6 induced by LPS, and has a very good efficacy in treating inflammatory damage caused by LPS.

[0126] The deposit information of the strain in this application is as follows:

[0127] Strain name: Bifidobacterium longum subsp. longum

[0128] The accession number is: CGMCC No.20105;

[0129] Deposit date: June 18, 2020;

[0130] Name of depository: General Microbiology Center of China Microbiological Culture Collection Administration;

[0131] Abbreviation of depository unit: CGMCC;

[0132] Address of the preservation unit: No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing.

[0133] The basic concepts have been described above. Obviously, for those skilled in the art, the above detailed disclosure is only for example and does not constitute a limitation of this specification. Although not explicitly stated here, those skilled in the art may make various modifications, improvements and corrections to this specification. Such modifications, improvements and corrections are suggested in this specification, so such modifications, improvements and corrections still belong to the spirit and scope of the exemplary embodiments of this specification.

[0134] At the same time, this specification uses specific words to describe the embodiments of this specification. For example, "one embodiment", "an embodiment", and / or "some embodiments" refer to a certain feature, structure or characteristic related to at least one embodiment of this specification. Therefore, it should be emphasized and noted that "one embodiment" or "an embodiment" or "an alternative embodiment" mentioned twice or more in different positions in this specification does not necessarily refer to the same embodiment. In addition, certain features, structures or characteristics in one or more embodiments of this specification can be appropriately combined.

[0135] In some embodiments, numbers describing the number of components and attributes are used. It should be understood that such numbers used in the description of the embodiments are modified by the modifiers "about", "approximately" or "substantially" in some examples. Unless otherwise specified, "about", "approximately" or "substantially" indicate that the numbers are allowed to vary by ±20%. Accordingly, in some embodiments, the numerical parameters used in the specification and claims are approximate values, which may change according to the required features of individual embodiments. In some embodiments, the numerical parameters should take into account the specified significant digits and adopt the general method of retaining digits. Although the numerical domains and parameters used to confirm the breadth of their range in some embodiments of this specification are approximate values, in specific embodiments, the setting of such numerical values ​​is as accurate as possible within the feasible range.

[0136] Finally, it should be understood that the embodiments described in this specification are only used to illustrate the principles of the embodiments of this specification. Other variations may also fall within the scope of this specification. Therefore, as an example and not a limitation, alternative configurations of the embodiments of this specification may be considered consistent with the teachings of this specification. Accordingly, the embodiments of this specification are not limited to the embodiments explicitly introduced and described in this specification.

Claims

1. A Bifidobacterium longum, whose preservation number is CGMCC No.20105.

2. The Bifidobacterium longum according to claim 1, characterized in that The 16S rRNA coding sequence of Bifidobacterium longum includes the nucleotide sequence shown in SEQ ID NO.

1.

3. A freeze-dried powder prepared from the Bifidobacterium longum according to claim 1 or 2.

4. The freeze-dried powder according to claim 3, characterized in that The Bifidobacterium longum is inactivated Bifidobacterium longum.

5. The method for preparing the freeze-dried powder according to claim 3 or 4, characterized in that: The Bifidobacterium longum according to claim 1 or 2 is freeze-dried to obtain a freeze-dried powder.

6. The preparation method according to claim 5, characterized in that: The Bifidobacterium longum is washed, inactivated, and freeze-dried to obtain freeze-dried powder.

7. The preparation method according to claim 6, characterized in that: The Bifidobacterium longum is washed with double distilled water; And / or, the inactivation condition is boiling water inactivation; And / or, the inactivation time is 1 to 5 minutes, preferably, the inactivation time is 2 minutes; And / or, the freeze-drying condition is -80°C vacuum freezing; And / or, the freeze-drying time is ≥ 2 hours.

8. Use of the Bifidobacterium longum according to claim 1 or 2 or the lyophilized powder according to claim 3 or 4 in the preparation of food, health products or medicines for preventing and / or treating inflammatory diseases; and / or, use in the preparation of food, health products or medicines for reducing the secretion of TNF-α, IL-6 or NO; And / or, use in preparing food, health products or medicines for enhancing immune function.

9. The use according to claim 8, characterized in that The inflammatory disease is caused by LPS or pathogenic bacteria containing LPS. Preferably, the inflammatory disease is caused by LPS-induced macrophages secreting pro-inflammatory factors TNF-α, IL-6 or NO.

10. A food, health product or medicine, characterized in that: The food, health product or medicine contains the Bifidobacterium longum according to claim 1 or 2 or the freeze-dried powder according to claim 3 or 4.

Citation Information

Cited By

  • Application of bifidobacterium longum in preparation of product for inhibiting growth and proliferation of bacteria

    CN119302426A

  • Use of bifidobacterium longum in the preparation of a product for inhibiting bacterial growth proliferation

    CN119302426B